Novo Nordisk withdraws from Ferrosan as Altor takes over
This article was originally published in Clinica
Executive Summary
Novo Nordisk has sold its 29% stake in fellow Danish firm Ferrosan to Swedish investment fund Altor 2003 Fund, which has also acquired all but a 30% stake from previous principal shareholder, Idosan. With the company now controlled by management and Altor, the aim will be to tap into Altor's financial resources to accelerate Ferrosan's growth.